Distribution of HLA class I altered phenotypes in colorectal carcinomas: high frequency of HLA haplotype loss associated with loss of heterozygosity in chromosome region 6p21

[1]  B. Seliger,et al.  Low frequency of HLA haplotype loss associated with loss of heterozygocity in chromosome region 6p21 in clear renal cell carcinomas , 2004, International journal of cancer.

[2]  Federico Garrido,et al.  MHC class I antigens, immune surveillance, and tumor immune escape , 2003, Journal of cellular physiology.

[3]  F. Garrido,et al.  Total loss of MHC class I in colorectal tumors can be explained by two molecular pathways: beta2-microglobulin inactivation in MSI-positive tumors and LMP7/TAP2 downregulation in MSI-negative tumors. , 2003, Tissue antigens.

[4]  R. Herrmann,et al.  SMAD4 is a predictive marker for 5-fluorouracil-based chemotherapy in patients with colorectal cancer , 2002, British Journal of Cancer.

[5]  T. Ørntoft,et al.  Gene expression in colorectal cancer. , 2002, Cancer research.

[6]  M. Rhyu,et al.  Genetic classification of colorectal cancer based on chromosomal loss and microsatellite instability predicts survival. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[7]  F. Garrido,et al.  Multiple mechanisms generate HLA class I altered phenotypes in laryngeal carcinomas: high frequency of HLA haplotype loss associated with loss of heterozygosity in chromosome region 6p21 , 2002, Cancer Immunology, Immunotherapy.

[8]  R. Vile.  Faculty Opinions recommendation of IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. , 2001 .

[9]  J. Trapani,et al.  Lymphocyte-mediated immunosurveillance of epithelial cancers? , 2001, Trends in immunology.

[10]  L. D. Tin,et al.  Microsatellite instability and high content of activated cytotoxic lymphocytes identify colon cancer patients with a favorable prognosis. , 2001, The American journal of pathology.

[11]  R. Schreiber,et al.  IFNγ and lymphocytes prevent primary tumour development and shape tumour immunogenicity , 2001, Nature.

[12]  E. Gehan,et al.  Phase I study in advanced cancer patients of a diversified prime-and-boost vaccination protocol using recombinant vaccinia virus and recombinant nonreplicating avipox virus to elicit anti-carcinoembryonic antigen immune responses. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  F. Garrido,et al.  Molecular strategies to define HLA haplotype loss in microdissected tumor cells. , 2000, Human immunology.

[14]  F. Garrido,et al.  Criteria to define HLA haplotype loss in human solid tumors. , 2000, Tissue antigens.

[15]  F. Garrido,et al.  High frequency of altered HLA class I phenotypes in laryngeal carcinomas. , 2000, Human immunology.

[16]  G. Fleuren,et al.  Multiple Genetic Alterations Cause Frequent and Heterogeneous Human Histocompatibility Leukocyte Antigen Class I Loss in Cervical Cancer , 2000, The Journal of experimental medicine.

[17]  P. Slootweg,et al.  Microsatellite Analysis of Microdissected Tumor Cells and 6p High Density Microsatellite Analysis in Head and Neck Squamous Cell Carcinomas with Down-Regulated Human Leukocyte Antigen Class I Expression , 2000, Laboratory Investigation.

[18]  S. Pettit,et al.  Selection of metastatic tumour phenotypes by host immune systems , 1999, The Lancet.

[19]  F. Garrido,et al.  Chromosome loss is the most frequent mechanism contributing to HLA haplotype loss in human tumors , 1999, International journal of cancer.

[20]  A. Strasser,et al.  The great escape: Is immune evasion required for tumor progression? , 1999, Nature Medicine.

[21]  J. Schlom,et al.  A Phase I study of active immunotherapy with carcinoembryonic antigen peptide (CAP-1)-pulsed, autologous human cultured dendritic cells in patients with metastatic malignancies expressing carcinoembryonic antigen. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[22]  P. Vihko,et al.  Loss of heterozygosity at 18q21 is indicative of recurrence and therefore poor prognosis in a subset of colorectal cancers , 1999, British Journal of Cancer.

[23]  S Srivastava,et al.  A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. , 1998, Cancer research.

[24]  H Nagura,et al.  CD8+ T cells infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer. , 1998, Cancer research.

[25]  R. Rosell,et al.  Allelic loss on chromosome 18q as a prognostic marker in stage II colorectal cancer. , 1998, Gastroenterology.

[26]  M. Hawn,et al.  Prognostic significance of allelic lost at chromosome 18q21 for stage II colorectal cancer. , 1998, Gastroenterology.

[27]  P. Stern,et al.  Implications for immunosurveillance of altered HLA class I phenotypes in human tumours. , 1997, Immunology today.

[28]  F. Garrido,et al.  High frequency of altered HLA class I phenotypes in invasive colorectal carcinomas. , 1996, Tissue antigens.

[29]  F. Garrido,et al.  High frequency of altered HLA class I phenotypes in invasive breast carcinomas. , 1996, Human immunology.

[30]  P. Stern,et al.  Natural history of HLA expression during tumour development. , 1993, Immunology today.

[31]  C. Boland.  Molecular basis for stool-based DNA tests for colorectal cancer: a primer for clinicians. , 2002, Reviews in gastroenterological disorders.

[32]  Boland Cr.  Molecular basis for stool-based DNA tests for colorectal cancer: a primer for clinicians. , 2002 .

[33]  F. Garrido,et al.  MHC antigens and tumor escape from immune surveillance. , 2001, Advances in cancer research.

[34]  P. Coulie,et al.  Antitumor immunity at work in a melanoma patient. , 1999, Advances in cancer research.